AR082458A1 - Combinacion que comprende un farmaco antipsicotico y un agonista de taar1 - Google Patents

Combinacion que comprende un farmaco antipsicotico y un agonista de taar1

Info

Publication number
AR082458A1
AR082458A1 ARP110102780A AR082458A1 AR 082458 A1 AR082458 A1 AR 082458A1 AR P110102780 A ARP110102780 A AR P110102780A AR 082458 A1 AR082458 A1 AR 082458A1
Authority
AR
Argentina
Prior art keywords
phenyl
lower alkyl
halogen
hydrogen
dihydro
Prior art date
Application number
Other languages
English (en)
Inventor
Marius Hoener
Susanne Raab
Celine Risterucci
Sabine Sewing
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44512842&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR082458(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR082458A1 publication Critical patent/AR082458A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Combinación farmacéutica destinada al tratamiento de la esquizofrenia y de episodios maniacos agudos asociados a trastornos bipolares, que comprende un compuesto que es activo sobre un receptor 1 asociado a aminas traza (agonista TAAR1) y un fármaco antipsicótico. Composiciones farmacéuticas que comprenden una combinación de un fármaco antipsicótico atípico y un agonista de TAAR1 tal como se describe en reivindicación 2, 3 y 4.Reivindicación 1: Combinación que comprende un fármaco antipsicótico atípico y un agonista de TAAR1. Reivindicación 2: Combinación según la reivindicación 1, que comprende olanzapina y un agonista de TAAR1 de fórmula (1) en la que: R1 es hidrógeno, deuterio, tritio, alquilo inferior, hidroxi, alcoxi inferior, alquilo inferior sustituido con halógeno, alcoxi inferior sustituido con halógeno, halógeno, fenilo opcionalmente sustituido con halógeno, o es feniloxi, bencilo, benciloxi, -COO-alquilo inferior, -O-(CH2)o-O-alquilo inferior, NH-cicloalquilo, cicloalquilo o tetrahidropirán-4-iloxi, en los que los sustituyentes para n > 1 pueden ser iguales o diferentes; X es un enlace, -CHR-, -CHRCHR’-, -OCH2-, -NRCHR’, -OCHRCHR’, -CH2OCHR-, -CH2CH2CH2-, -SCH2-, -S(O)2CH2-, -CH2SCH2-, -CH2N(R)CH2-, -cicloalquil-CH2- o SiRR’-CH2-; R/R’ puede ser, independientemente uno de otro, hidrógeno, alquilo inferior o alquilo inferior sustituido con halógeno; R2 es hidrógeno, fenilo o alquilo inferior; Y es fenilo, naftilo, tiofenilo, piridinilo, cicloalquilo, 1,2,3,4-tetrahidronaftalén-2-ilo, 2,3-dihidrobenzo[1,4]dioxin-6-ilo o benzo[1,3jdioxol-5-ilo; n es 0, 1, 2 ó 3; o es 2 ó 3; o una sal de adición de ácido farmacéuticamente aceptable de los mismos, o un agonista de TAAR1 de fórmula (2) en la que R es hidrógeno o alquilo inferior; R1 es -(CH2)n-(O)o-heterocicloalquilo, opcionalmente sustituido con alquilo inferior, hidroxi, halógeno, o con -(CH2)p-arilo; n es 0, 1 ó 2; o es 0 ó1; p es 0, 1 ó 2; R2 es cicloalquilo, heterocicloalquilo, o es arilo o heteroarilo, en el que los anillos aromáticos se sustituyen opcionalmente con uno o dos sustituyentes, seleccionados de entre alquilo inferior, halógeno, heteroarilo, CF3, OCF3, OCH2CF3, alcoxi inferior, CH2-alcoxi inferior, alquinilo inferior o ciano; X es un enlace, -NR’-, -CH2NH-, -CHR’’-, -(CH2)q-O- o -(CH2)2-; R’ es hidrógeno o alquilo inferior; R’’ es hidrógeno, alquilo inferior, alcoxi inferior; q es 0, 1 ó 2; o una sal de adición de ácido farmacéuticamente aceptable de los mismos. Reivindicación 3: Combinación según la reivindicación 2, que comprende olanzapina y un agonista de TAAR1 de fórmula (3) en la que R1 es hidrógeno, alquilo inferior, hidroxi, alcoxi inferior, alquilo inferior sustituido con halógeno, alcoxi inferior sustituido con halógeno o halógeno, en el que los sustituyentes para n = 2 pueden ser iguales o diferentes; X es un enlace, -NRCHR’, -CHRCHR’ o -OCHRCHR’; R/R’ puede ser, independientemente uno de otro, hidrógeno, alquilo inferior; n es 1 ó 2; o un agonista de TAAR1 de fórmula (2) en la que R es hidrógeno; R1 es pirrolidinilo; R2 es arilo o heteroarilo, en el que los anillos aromáticos se sustituyen opcionalmente con halógeno; X es un enlace o -NR’-; R’ es hidrógeno o alquilo inferior; o una sal de adición de ácido farmacéuticamente aceptable de los mismos. Reivindicación 4: Combinación según las reivindicaciones 1 a 3, que comprende olanzapina y un agonista de TAAR1, siendo los agonistas de TAAR1: S1 = (S)-4-((S)-2-fenil-butil)-4,5-dihidro-oxazol-2-ilamina, S2 = (S)-4-(3-fluoro-2-metil-fenil)-4,5-dihidro-oxazol-2-ilamina, S3 = (S)-4-(4-cloro-2-trifluorometil-fenil)-4,5-dihidro-oxazol-2-ilamina, S4 = (S)-4-[(etil-fenil-amino)-metil]-4,5-dihidro-oxazol-2-ilamina, S5 = 3-[(S)-1-((S)-2-amino-4,5-dihidro-oxazol-4-ilmetil)-propoxi]-fenol, S6 = (4-pirrolidin-3-il-fenil)-amida de ácido 5-cloro-piridin-2-carboxílico, S7 = 4-cloro-N-(4-pirrolidin-3-il-fenil)-benzamida, S8 = 1-(5-cloro-piridin-2-il)-3-(4-pirrolidin-3-il-fenil)urea, S9 = (S)-4-[(S)-1-(4-fluoro-fenil)-etoximetil]-4,5-dihidro-oxazol-2-ilamina, S10 = {4-[2-((S)-2-amino-4,5-dihidro-oxazol-4-il)-etil]-fenil}-amida de ácido 5-cloro-pirimidin-2-carboxílico, S11 = N-{4-[2-((S)-2-amino-4,5-dihidro-oxazol-4-il)-etil]-fenil}-4-cloro-benzamida, S12 = (R)-2-cloro-6-metil-N-(4-(morfolin-2-il)fenil)isonicotinamida, S13 = (S)-N-(4-(morfolin-2-il)fenil)-6-(2,2,2-trifluoroetoxi)nicotinamida, S14 = (S)-N-(4-(morfolin-2-il)fenil)-2-(trifluorometil)isonicotinamida, S15 = (S)-1-(4-fluorobencil)-3-(4-(morfolin-2-il)fenil)urea, S16 = (S)-1-(3-cianofenil)-3-(4-(morfolin-2-il)fenil)urea, y S17 = (S)-6-cloro-N-(4-(morfolin-2-il)fenil)nicotinamida. Reivindicación 5: Compuesto S2 = (S)-4-(3-fluoro-2-metil-fenil)-4,5-dihidro-oxazol-2-ilamina, comprendido por las fórmulas (1) ó (3) según las reivindicaciones 2 y 3. Reivindicación 6: Combinación según las reivindicaciones 1 a 4, que comprende olanzapina y un agonista de TAAR1 para el tratamiento de la esquizofrenia y de los episodios de manía asociados al trastorno bipolar, con una incidencia reducida de síndrome metabólico. Reivindicación 7: Combinación según la reivindicación 6, que comprende olanzapina y un agonista de TAAR1 para el tratamiento de la esquizofrenia y de los episodios de manía asociados al trastorno bipolar, con eficacia antidiabética. Reivindicación 9: Combinación según la reivindicación 8, que comprende olanzapina y un agonista de TAAR1 para el tratamiento de la esquizofrenia y de los episodios de manía asociados al trastorno bipolar, con eficacia antidiabética, que resulta en la reducción de la masa grasa y el peso corporal. Reivindicación 16: Método para el tratamiento de la esquizofrenia y los episodios maníacos asociados al trastorno bipolar según la reivindicación 15, en el que la incidencia reducida de síndrome metabólico resulta de la eficacia antidiabética con reducción de las excursiones de la glucosa sanguínea, la masa grasa y el peso corporal, que comprende administrar en un ser humano que necesita del mismo una cantidad efectiva de una combinación que comprende un fármaco antipsicótico atípico y un agonista de TAAR1.
ARP110102780 2010-08-02 2011-08-02 Combinacion que comprende un farmaco antipsicotico y un agonista de taar1 AR082458A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10171560 2010-08-02

Publications (1)

Publication Number Publication Date
AR082458A1 true AR082458A1 (es) 2012-12-12

Family

ID=44512842

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110102780 AR082458A1 (es) 2010-08-02 2011-08-02 Combinacion que comprende un farmaco antipsicotico y un agonista de taar1

Country Status (24)

Country Link
US (2) US9132136B2 (es)
EP (1) EP2600853A1 (es)
JP (2) JP5749802B2 (es)
KR (1) KR101455548B1 (es)
CN (1) CN103068379A (es)
AR (1) AR082458A1 (es)
AU (1) AU2011287701A1 (es)
BR (1) BR112013002518A2 (es)
CA (1) CA2802935A1 (es)
CL (1) CL2013000313A1 (es)
CO (1) CO6761298A2 (es)
CR (1) CR20120663A (es)
EA (1) EA024703B1 (es)
EC (1) ECSP13012414A (es)
MA (1) MA34458B1 (es)
MX (1) MX340489B (es)
MY (1) MY166955A (es)
NZ (1) NZ604592A (es)
PE (1) PE20130497A1 (es)
SG (1) SG187125A1 (es)
TW (1) TWI511728B (es)
UA (1) UA112527C2 (es)
WO (1) WO2012016879A1 (es)
ZA (1) ZA201300431B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8802673B2 (en) * 2011-03-24 2014-08-12 Hoffmann-La Roche Inc Heterocyclic amine derivatives
US9073911B2 (en) * 2011-06-09 2015-07-07 Hoffmann-La Roche Inc. Pyrazole derivatives
US9029370B2 (en) * 2011-06-10 2015-05-12 Hoffmann-La Roche Inc. Substituted benzamide derivatives
MX354815B (es) * 2012-01-12 2018-03-22 Hoffmann La Roche Derivados heterociclicos como receptores asociados con las aminas traza (taars).
AU2013346882B2 (en) * 2012-11-16 2017-05-04 F. Hoffmann-La Roche Ag Process for the preparation of 2-trifluoromethyl isonicotinic acid and esters
KR20160097291A (ko) 2013-12-11 2016-08-17 에프. 호프만-라 로슈 아게 키랄 2-아릴 모폴린의 제조 방법
WO2015165085A1 (en) * 2014-04-30 2015-11-05 F.Hoffmann-La Roche Ag Morpholin-pyridine derivatives
CN109071518A (zh) * 2016-05-04 2018-12-21 普渡制药公司 噁唑啉假二聚体、药物组合物及其用途
SG11202007823PA (en) 2018-02-16 2020-09-29 Sunovion Pharmaceuticals Inc Salts, crystal forms, and production methods thereof
UA127357C2 (uk) 2018-04-18 2023-07-26 Констеллатіон Фармацеутікалс, Інк. Модулятори метилмодифікуючих ферментів, композиції та їх використання
CA3100977A1 (en) 2018-05-21 2019-11-28 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
IL297248A (en) 2020-04-14 2022-12-01 Sunovion Pharmaceuticals Inc (s)-(5,4-dihydro-7h-thiano[3,2-c]pyran-7-yl)-n-methylmethanamine for the treatment of neurological and psychiatric disorders
KR20230005888A (ko) * 2020-05-09 2023-01-10 선전 프로파운드 뷰 파마슈티칼 테크놀로지 컴퍼니 리미티드 비정형 항정신병약물에 의해 유발되는 부작용의 치료
JP2024511828A (ja) * 2021-03-29 2024-03-15 シューチン バイオファーマ カンパニー リミテッド スピロ環含有誘導体、その調製方法及び使用
CN114288304A (zh) * 2021-12-31 2022-04-08 江苏海洋大学 一种抗精神分裂症组合物及其应用
WO2024013383A1 (en) 2022-07-15 2024-01-18 F. Hoffmann-La Roche Ag Mutant ketoreductase with increased ketoreductase activity as well as methods and uses involving the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1838716T3 (pl) 2005-01-05 2011-09-30 Lilly Co Eli Dihydrat embonianu olanzapiny
PL385455A1 (pl) * 2005-04-22 2008-11-24 Teva Pharmaceuticals Usa,Inc. Doustna rozpadająca się farmaceutyczna tabletka preparatów olanzapiny
KR20070022539A (ko) 2005-08-22 2007-02-27 홍진표 지프라시돈 또는 그의 대사산물을 함유하는 항비만 조성물
KR101174191B1 (ko) 2007-02-02 2012-08-14 에프. 호프만-라 로슈 아게 중추 신경계 장애의 치료용 ｔａａｒ1 리간드로서 2-아미노옥사졸린
WO2008098857A1 (en) 2007-02-15 2008-08-21 F. Hoffmann-La Roche Ag 2-aminooxazolines as taar1 ligands
CN101765425A (zh) 2007-08-02 2010-06-30 弗·哈夫曼-拉罗切有限公司 苯甲酰胺衍生物用于治疗cns障碍的用途
CA2728480A1 (en) 2008-07-24 2010-01-28 F. Hoffmann-La Roche Ag 4,5-dihydro-oxazol-2-yl derivatives
CA2733378C (en) 2008-08-05 2017-04-25 Omeros Corporation Pde10 inhibitors and related compositions and methods
US8354441B2 (en) * 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
US8293954B2 (en) * 2010-03-10 2012-10-23 Honeywell International Inc. Catalyst life improvement for the vapor phase manufacture of 1-chloro-3,3,3-trifluoropropene

Also Published As

Publication number Publication date
EA024703B1 (ru) 2016-10-31
US9132136B2 (en) 2015-09-15
SG187125A1 (en) 2013-02-28
CA2802935A1 (en) 2012-02-09
JP2015145408A (ja) 2015-08-13
EP2600853A1 (en) 2013-06-12
MA34458B1 (fr) 2013-08-01
CL2013000313A1 (es) 2013-05-03
JP2013536181A (ja) 2013-09-19
TW201206912A (en) 2012-02-16
ECSP13012414A (es) 2013-03-28
NZ604592A (en) 2015-02-27
WO2012016879A1 (en) 2012-02-09
US20120028964A1 (en) 2012-02-02
MY166955A (en) 2018-07-25
BR112013002518A2 (pt) 2016-05-31
JP5749802B2 (ja) 2015-07-15
KR20130070629A (ko) 2013-06-27
KR101455548B1 (ko) 2014-10-27
AU2011287701A1 (en) 2013-01-10
MX2013000745A (es) 2013-03-05
PE20130497A1 (es) 2013-04-22
CN103068379A (zh) 2013-04-24
MX340489B (es) 2016-07-11
EA201291476A1 (ru) 2013-06-28
US20130345201A1 (en) 2013-12-26
UA112527C2 (uk) 2016-09-26
TWI511728B (zh) 2015-12-11
ZA201300431B (en) 2013-09-25
CO6761298A2 (es) 2013-09-30
CR20120663A (es) 2013-04-01

Similar Documents

Publication Publication Date Title
AR082458A1 (es) Combinacion que comprende un farmaco antipsicotico y un agonista de taar1
RU2454411C2 (ru) Производные хинолина
JP2016538313A5 (es)
RU2012127760A (ru) Bcl-2-селективные апоптоз-индуцирующие средства для лечения рака и иммунных заболеваний
RU2006145205A (ru) Терапевтические соединения: пиридин в качестве каркаса
NZ612544A (en) Heterocyclic compounds suitable for the treatment of dyslipidemia
RU2017120217A (ru) 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1
RU2010137114A (ru) Амидные производные как позитивные аллостерические модуляторы и способы их применения
RU2017116598A (ru) Соединения и композиции для модуляции киназной активности мутантов egfr
NZ588652A (en) Carboxamide compounds for the treatment of metabolic disorders
RU2010110640A (ru) Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ
PE20120650A1 (es) Acetamidas sustituidas por n-(hetero)-arilo y 2-(hetero)-arilo, como moduladores de la senalizacion de wnt
RU2012116877A (ru) Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы
RU2012127790A (ru) Индуцирующие апоптоз агенты для лечения рака и иммунных и аутоиммунных заболеваний
HRP20160287T1 (hr) Antagonisti cgrp receptora
HRP20201430T1 (hr) Spojevi 6-heterociklil-4-morfolin-4-ilpiridin-2-ona korisni za liječenje karcinoma i dijabetesa
JP2008500336A5 (es)
BR112012017713A2 (pt) Aminopiridina, formulação farmacêutica, processo para a preparação de um derivado de aminopiridina, intermediário, e, uso de uma aminopiridina ou de uma formulação farmacêutica
JP2013516395A5 (es)
RU2009148673A (ru) Производные пиразинона и их применение для лечения легочных заболеваний
RU2018104868A (ru) 2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
PE20130215A1 (es) Nuevos derivados de ciclohexilamina que tienen actividad como agonistas adrenergicos beta2 y como antagonistas muscarinicos m3
RU2013130879A (ru) Производные оксазолилметилового эфира в качестве агонистов рецептора alx
RU2013132930A (ru) Производное пиразола

Legal Events

Date Code Title Description
FB Suspension of granting procedure